Currently, the focus is on defining sarcomas based on their histologic subtype, molecular profile and genetic changes, rather than their anatomic origin, which will aid the development of novel therapies, like MDM2 and CDK4/6 inhibitors. Here, MDM2 is linked to sarcoma.